Mixed-species Plasmodium falciparum and Plasmodium ovale malaria in a paediatric returned traveller by Heather Senn et al.
Senn et al. Malaria Journal 2014, 13:78
http://www.malariajournal.com/content/13/1/78CASE REPORT Open AccessMixed-species Plasmodium falciparum and
Plasmodium ovale malaria in a paediatric returned
traveller
Heather Senn1, Nadia Alattas2, Andrea K Boggild3,4,5 and Shaun K Morris2,6*Abstract
Malaria is a common and potentially fatal cause of febrile illness in returned travellers. Endemic areas for different
malaria parasites overlap, but mixed species infections are rare. An adolescent male returned from a trip to Ghana
in late summer 2013. He subsequently presented with blood smears positive for two species of malaria parasite,
Plasmodium falciparum and Plasmodium ovale, on two isolated hospital visits within a six-week period. The
epidemiology of mixed infections, likely pathophysiology of his presentation, and the implications for malaria
testing and treatment in returned travellers are discussed.
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Rapid diagnostic testBackground
Malaria remains the most commonly identified cause of
fever in returned travellers, with the majority of infec-
tions acquired in sub-Saharan Africa [1]. Malaria can be
caused by several different species of Plasmodium para-
sites with the largest burden of mortality and morbidity
being due to Plasmodium falciparum. While Plasmo-
dium species have different geographical distributions,
there are areas of significant overlap. Thus, individuals
may be infected with more than one species at any given
time though this is rare in returned travellers [2]. Mixed
infections, where more than one species are present either
in the blood or liver stage of infection at one time, can
have varied presentations. Different species have different
clinical features and also require different treatments.
Recently, a Canadian adolescent presented with symp-
toms of malaria twice within a six-week period to The
Hospital for Sick Children (SickKids) in Toronto follow-
ing a trip to West Africa. On both visits, he had multiple
positive blood smears and each set was identified as a
different Plasmodium species.* Correspondence: Shaun.morris@sickkids.ca
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A previously healthy 16-year-old male went on a volunteer
trip to Ghana for three weeks in June and July, 2013. He
did not take malaria prophylaxis. He had been on a similar
volunteer trip to Kenya one year previously during which
he took appropriate malaria prophylaxis and received
hepatitis A, typhoid and yellow fever vaccinations prior to
departure. Ten days after his return from Ghana, he pre-
sented to a local emergency department with a four-day
history of fever, chills, headaches, nausea, and vomiting. A
blood smear was positive for malaria parasites, later iden-
tified as P. falciparum, with a parasitaemia of 2.5% by the
Public Health Ontario Laboratory (PHOL). Plasmodium
falciparum-specific histidine rich protein-2 (HRP-2) was
detected by rapid diagnostic test (RDT), while Plasmo-
dium genus aldolase was undetectable. The patient was
transferred to SickKids with findings of hypotension, ele-
vated liver enzymes (Alanine aminotransferase (ALT) 134
U./L; aspertate aminotransferase (AST) 106 U/L; Gamma
glutamyl transferase (GGT) 55 U/L), and thrombocyto-
paenia (platelets 19 × 10^9/L). A subsequent pre-treatment
blood smear was positive for P. falciparum with 2.4%
parasitaemia. He was treated with a three-day course of
intravenous artesunate and oral atovaquone/proguanil.
On day 5 of his admission he had clinically improved, and
was discharged home with normalizing blood work trendsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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remained detectable by RDT despite an absence of para-
sitemia by thick and thin film microscopy. He was sub-
sequently seen in follow-up in the Infectious Diseases
clinic at SickKids one week later and reported to be
asymptomatic with a repeat blood smear confirming an
absence of parasitaemia from PHOL.
However, the patient returned to the emergency room
at SickKids one month later with a two-day history of
recurring symptoms of headache, nausea and vomiting
without a fever. A blood smear was performed which
was positive for malaria parasites with a parasitaemia
level of <0.1%. The remainder of his laboratory results
were within normal limits. It was initially thought that
he was experiencing a recrudescence of P. falciparum
malaria. Repeat blood smears were drawn on three con-
secutive days and were sent to PHOL for species identi-
fication while he was treated with a three-day course of
oral atovaquone/proguanil. His symptoms were com-
paratively mild and resolved quickly and he was dis-
charged home within 48 hours. He was followed up in
clinic after four days, at which time species identification
was available. All three blood smears identified Plasmo-
dium ovale with <0.1% parasitaemia. Again, P. falcip-
arum HRP2 was detectable by RDT, while Plasmodium
genus aldolase was undetectable. Due to the discrepancy
between microscopy and RDT, Plasmodium genus-
specific and species-specific quantitative real time PCR
(qPCR) targeting 18S rRNA was performed as described
[3]. qPCR confirmed isolated P. ovale infection. The pa-
tient was treated with four doses of chloroquine and,
after ruling out G6PD deficiency, he subsequently began
a 14-day course of primaquine. Clinic follow-up two
weeks after completing treatment confirmed he was doing
well and a repeat blood smear at that time was negative.
Discussion
Mixed species malaria infections are rare in travellers,
comprising 2.1% of the 1,140 cases of malaria logged by
the GeoSentinel Surveillance network based on treating
physician diagnosis between 1997 and 2002 [2]. Mixed
P. falciparum and P. ovale infections are especially un-
common, with only three instances (0.3%) reported in
the above study. This statistic is in large part due to the
rarity of P. ovale itself which accounted for only 5% of
all malaria infections. A more recent study systematically
tested over 1200 returned travellers from Italy who had
at least 1 symptom of malaria with highly sensitive PCR
testing. Of the 196 patients who tested positive for mal-
aria, 3.1% had mixed-species infections including 2.0%
testing positive for P. falciparum and P. ovale. Plasmo-
dium ovale monoinfection accounted for 3.1% of malaria
cases in this study [4]. In Ontario, over a six-year-
period, 33 specimens from 29 patients with isolated P.ovale infection were identified by PHOL [3], underscor-
ing the rarity of this infection in returned travellers.
Mixed P. ovale and P. falciparum infections are also
uncommon in areas where malaria is endemic. A study
that followed 830 children in Burkina Faso from 2007–
2010 found study participants had an overall malaria
prevalence of 71% over the three years, and among
those who presented with malaria, the rate of P. falcip-
arum and P. ovale mixed infection was 0.72% [5]. Plas-
modium ovale itself, again, was quite rare accounting
for 1.08% of all recorded malaria infections.
While reported rates of P. ovale malaria are consist-
ently low, there is evidence to suggest that infection with
this species may actually be more common than most
studies suggest. A research group in Senegal followed
101 children and 105 adults over a four-month malaria
season with regular thick blood films regardless of the
presence or absence of signs and symptoms of infection
[6]. Although only three clinically significant P. ovale in-
fections were documented, 48.5% of children and 32.5%
of adults had blood films positive for P. ovale at some
point during the study period suggesting that while in-
fection with P. ovale may be common, the majority of
infections are subclinical.
The two Plasmodium species have different life cycles
and behaviours, accounting for the immediate and more
severe presentation of P. falciparum malaria and delayed
and milder course of P. ovale malaria in this patient.
Plasmodium falciparum cycles through a transient liver
phase, following which multiple schizonts rupture sim-
ultaneously and the infection proceeds to the symptom-
atic blood stage. This almost always occurs within two
months of exposure. In contrast, P. ovale has a promin-
ent liver hypnozoite phase. Parasites remain dormant in
this stage and may persist for years. Presentation of P.
ovale malaria is often delayed and hypnozoites rupture
asynchronously producing intermittent symptoms of a
milder nature. Specific treatment is required to target the
hypnozoite phase to prevent relapse of infection. It is
worth noting that the presentation of P. ovale and P.
falciparum mixed infections cannot always be ex-
pected to follow this patient’s pattern. The timing of infec-
tion, variability of hypnozoite phase duration, interactions
between species and other factors may play a role. A recent
case report described a mixed-species infection where the
patient presented first with P. ovale malaria with a subse-
quent delayed presentation of P. falciparum [7].
It is likely that the patient contracted both Plasmo-
dium species during his recent trip to Ghana, with the
presentation of P. ovale being either initially masked by
the higher parasitaemia of P. falciparum or delayed
while it remained in the hypnozoite phase. The possibil-
ity that this patient acquired his P. ovale infection during
his trip to Kenya the year prior cannot be excluded.
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quitoes, rates of confirmed mosquito co-infection are
very low and most cases of mixed malaria infection are
thought to be acquired from two separate inoculations
[8]. Rapid diagnostic testing (RDT) is routinely per-
formed as part of malaria screening to compliment
blood smear identification in haematology and public
health laboratories in Canada [9]. Although approved
RDTs can detect P. falciparum and Plasmodium vivax,
specific testing for P. ovale is not available. Current as-
says developed to detect mixed malaria infections have
suboptimal sensitivity for the diagnosis of P. ovale
[10,11]. An added disadvantage of RDTs is their pro-
longed detection of circulating antigen for weeks follow-
ing effective malaria treatment [12], which can confuse
the clinical picture. Persistent antigenemia, as seen in
this case, can lead to an over-diagnosis of treatment fail-
ure, or misattribution of new symptoms to a relapsed or
recrudesced prior infection.
The more sensitive malaria PCR, a costly test which is
not routinely performed, is helpful in arbitrating incon-
gruent results of microscopy and RDT, in identifying
very low parasitemia infections, and in identifying those
parasites with aberrant morphology on microscopy
[4,13,14]. As described above, this test is available at
PHOL, which uses one genus-specific and two duplex,
species-specific real time quantitative PCR (qPCR) as-
says targeting the 18S rRNA region for the identification
of Plasmodium species as described [3].
While appropriate prophylaxis would likely have pre-
vented P. falciparum infection, it may not have pre-
vented P. ovale infection. There have been case reports
of returned travellers receiving appropriate prophylaxis
who nevertheless present with P. ovale malaria [15,16].
This has also been reported for P. vivax, another Plas-
modium species with a hypnozoite phase [17,18]. How
frequently this occurs is unknown. Typical drugs used
for prophylaxis such as atovaquone/proguanil do not
successfully treat the liver phase of malaria infection,
and any remaining liver schizonts can progress to the
blood phase of infection once prophylaxis has stopped.
The Centers for Disease Control thus recommend
primaquine prophylaxis in areas of high P. vivax preva-
lence as well as a terminal prophylaxis in long-term travel-
lers to endemic areas of relapsing malaria [19]. Relapses
can occur up to several years after the initial infection for
P. ovale, raising the possibility that while not likely, the pa-
tient described in this report may have contracted P. ovale
during his previous trip to Kenya even though he took ap-
propriate prophylaxis [20-23]. His recent symptoms could
have been his first presentation, or he may have had previ-
ous reactivations that were not recognized as malaria. This
highlights the importance of considering malaria in the
differential diagnosis of symptomatic patients for monthsto years after travel to endemic areas, particularly if they
present with a history of intermittent, recurrent illness.
In contrast to P. falciparum, P. ovale is almost uni-
versally chloroquine sensitive. Very few studies have
attempted to determine the sensitivity of the blood
stage of P. ovale to alternative therapies such as atova-
quone/proguanil. One small study from 1996 treated
seven adults presenting with Plasmodium malariae or
P. ovale malaria with atovaquone and proguanil [24].
Each of the patients was cured of their infection. An-
other case report documented a single adult patient
who cleared a P. ovale infection with atovaquone/pro-
guanil [25]. The Centers for Disease Control guidelines
for malaria treatment state that treatment regimens ef-
fective for P. falciparum are also acceptable for P. ovale
[19]. Nevertheless, given the sparse data available, and
because the patient’s most recent blood smear, taken
on the last day of atovaquone/proguanil treatment,
remained positive, the confirmed P. ovale infection was
treated with chloroquine for 48 hours to clear the
blood phase, followed by a two-week course of prima-
quine to clear the hypnozoite phase.
Conclusion
In the summer of 2013, a paediatric returned traveller
presented to SickKids with a rare, mixed-species malaria
infection. He initially presented with more severe P. fal-
ciparum malaria, then returned one month later with
milder symptoms and a blood smear positive for P.
ovale. Mixed malaria infections are rare in returned trav-
ellers, and P. ovale itself is a rare cause of documented
malaria that often has mild symptoms, delayed presenta-
tion, and may cause subclinical infections in the majority
of cases. Compared to other species of malaria, little is
known about this parasite’s actual prevalence and re-
sponse to different anti-malarial therapies. This case
highlights the value of accurate speciation of malaria
blood films, and follow-up to ensure patients receive ap-
propriate treatment including radical cure, if indicated,
of the identified parasite. It also raises the possibility that
more sensitive testing, such as PCR, may be useful in the
setting of recurrent illness. It demonstrates the import-
ance of considering malaria in the differential diagnosis of
returned travellers with delayed symptoms, regardless of
their use of prophylactic medications or previous malaria
treatment. More generally, this case reinforces the im-
portance of pre-travel physician counselling and adequate
malaria prophylaxis for trips to endemic areas.
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